Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1379)
  2. Journal Article (1159)
  3. Review (130)
  4. Editorial (65)
  5. Research Letter (36)
  6. Correspondence (26)
  7. Book Section (25)
  8. Guidelines (12)
  9. Conference Paper (2)
  10. Miscellaneous (2)
Groups
  1. Hematology-Oncology Fellows (2763)
  2. Department of Medicine (2720)
  3. Solid Tumor Oncology Division (2017)
  4. Hematologic Malignancies, Division of (1337)
  5. GSK Faculty (1233)
  6. Department of Pathology and Laboratory Medicine (988)

More Groups

People
  1. Michael Berger (220)
  2. Marc Ladanyi (198)
  3. Pedram Razavi (184)
  4. Michael Offin (177)
  5. Sergio Giralt (171)
  6. David Solit (169)

More People

Years
  1. 2025 (223)
  2. 2024 (414)
  3. 2023 (330)
  4. 2022 (377)
  5. 2021 (339)
  6. 2020 (323)

More Years

Publications
  1. Journal of Clinical Oncology (568)
  2. Blood (299)
  3. Annals of Oncology (107)
  4. Clinical Cancer Research (102)
  5. Journal of Thoracic Oncology (96)
  6. Cancer Research (87)

More Publications

Publishers
  1. American Society of Clinical Oncology (645)
  2. Elsevier Inc. (344)
  3. American Society of Hematology (339)
  4. American Association for Cancer Research (241)
  5. Nature Publishing Group (202)
  6. Oxford University Press (157)

More Publishers

Results (2836)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Systematic evaluation of GAPs and GEFs identifies ARHGAP45 as a targetable leukemia-specific dependency
    Meeting Abstract

    Zhang, P.; Cao, Z.; Pan, X.; Liu, Y.; Castro, C.; Kim, W. J.; Fujino, T.; Lewis, J.; Rahman, J.; Shahid, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Barriers to immune effector cell therapy: Rapid disease progression, concern for toxicity, and lack of appropriate trials drive non-receipt after referral at a large academic center
    Meeting Abstract

    Valtis, Y. K.; Chin, K. K.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; Brooklyn, C.; Goldstein, T.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase II study of longitudinal geriatric assessment with risk-adapted interventions to reduce non-relapse mortality in allogeneic hematopoietic cell transplantation for older patients with advanced myeloid malignancies
    Meeting Abstract

    Lin, R. J.; Kim, S. J.; Brown, S.; Hanley, D. M.; Engstler, D. E.; Politikos, I.; Gyurkocza, B.; Tamari, R.; Papadopoulos, E. B.; Saldia, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Immune-MRD status informs tumor-MRD outcome prognostication in multiple myeloma patients on lenalidomide maintenance
    Meeting Abstract

    Firestone, R. S.; Simhal, A. K.; McAvoy, D.; Jurgens, E. M.; GarceĢs, J. J.; Nemirovsky, D.; Derkach, A.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Cross-talk between leukemic blasts and T cells drives targetable T cell dysfunction in the AML tumor microenvironment
    Meeting Abstract

    DeWolf, S.; Ceglia, N.; Zatzman, M.; Gipson, B.; Elhanati, Y.; Katsamakis, Z.; Lees, H.; Weis, K.; Yepes, G.; Oliveira, B.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
    Meeting Abstract

    Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Development of a novel prognostic score for relapsed/refractory mature T-cell and NK-cell lymphomas (PIRT): Results from a global peripheral T-cell lymphoma (PETAL) Consortium
    Meeting Abstract

    Koh, M. J.; Han, J. X.; Boussi, L.; Sorial, M. N.; McCabe, S. M.; Peng, L.; Singh, S.; Eche-Ugwu, I. J.; Gabler, J.; Fernandez Turizo, M. J. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Dual-targeted therapy with ruxolitinib plus duvelisib for T-cell lymphoma
    Meeting Abstract

    Moskowitz, A.; Ganesan, N.; Chang, T.; Davey, T.; Hancock, H.; Smith, M.; Assini, A.; Sarmasti, L.; Miller, T.; Gibaldi, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outpatient vs inpatient HiDA consolidation for AML: The MSKCC experience
    Meeting Abstract

    Boussi, L.; Burton, H.; Derkach, A.; Nemirovsky, D.; Ciervo, J.; Tallman, M. S.; Stein, E. M.; Cai, S.
    Blood (2024)

    Fulltext@MSK | Save
  • Development of CAR T cells targeting U5 snRNP200 for the treatment of acute myeloid and B-lymphoid leukemias
    Meeting Abstract

    Fujino, T.; Lewis, J.; Chen, B. Y.; Sievers, Q.; Cai, W.; Yoo, S.; Mathew, S.; Souness, S.; Burns, E. R.; Um, J. S.; more...
    Blood (2024)

    Fulltext@MSK | Save